Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.KRRO · Entity 6388 | Chief Scientific Officer | July 15, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,797 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 7,500 · Balance 25,797 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date. F2: Includes 18,358 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,858 shares that will vest on December 15, 2026, 3,750 shares that will vest on July 15, 2027, and 3,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.
F2: Includes 18,358 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,858 shares that will vest on December 15, 2026, 3,750 shares that will vest on July 15, 2027, and 3,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 11:14 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-306743 · ownership.xml · nonDerivative · entry 1 Vincent Loic A · CIK 0002063400 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,797 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date. F2 · balance_after: Includes 18,358 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,858 shares that will vest on December 15, 2026, 3,750 shares that will vest on July 15, 2027, and 3,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:11 UTC | Korro Bio, Inc. KRRO · Entity 6388 | SaleCommon Stock | 3,418 | $10.83 | $37,016.94 |
DisclosureSEC source: 0001193125-26-274156 · ownership.xml · nonDerivative · entry 1 Vincent Loic A · CIK 0002063400 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,297 F1 · kind: Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan). F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request. F3 · balance_after: Includes 10,858 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:14 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001193125-26-035564 · ownership.xml · derivative · entry 1 Vincent Loic A · CIK 0002063400 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments commencing from February 2, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:09 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantCommon Stock | 21,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-320859 · ownership.xml · nonDerivative · entry 1 Vincent Loic A · CIK 0002063400 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,715 F1 · security: Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on June 15, 2026 and 50% on December 15, 2026, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 01:46 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $15.95 | $0.00 |
DisclosureSEC source: 0000950170-25-048847 · ownership.xml · derivative · entry 1 Vincent Loic A · CIK 0002063400 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-03-30 F1 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.